These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2954027)

  • 1. Influence of renal and hepatic function on pharmacodynamics and pharmacokinetics of non-depolarizing muscle relaxants.
    Booij LH
    Pharm Weekbl Sci; 1987 Apr; 9(2):56-60. PubMed ID: 2954027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the nondepolarizing neuromuscular relaxants applied to calculation of bolus and infusion dosage regimens.
    Shanks CA
    Anesthesiology; 1986 Jan; 64(1):72-86. PubMed ID: 2935053
    [No Abstract]   [Full Text] [Related]  

  • 3. [Metabolism and pharmacokinetics of atracurium].
    Colin JN; Singlas E
    Ann Fr Anesth Reanim; 1985; 4(6):465-70. PubMed ID: 2936284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of muscle relaxants in patients with burns.
    Martyn J; Goldhill DR; Goudsouzian NG
    J Clin Pharmacol; 1986; 26(8):680-5. PubMed ID: 2947935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure.
    Cook DR; Freeman JA; Lai AA; Robertson KA; Kang Y; Stiller RL; Aggarwal S; Abou-Donia MM; Welch RM
    Anesth Analg; 1991 Feb; 72(2):145-50. PubMed ID: 1824669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal muscle relaxants: pharmacodynamics and pharmacokinetics in different patient groups.
    Booij LH; Vree TB
    Int J Clin Pract; 2000 Oct; 54(8):526-34. PubMed ID: 11198732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of neuromuscular blocking drugs.
    Agoston S; Vandenbrom RH; Wierda JM
    Clin Pharmacokinet; 1992 Feb; 22(2):94-115. PubMed ID: 1551294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of the non-depolarising muscle relaxants.
    Ramzan MI; Somogyi AA; Walker JS; Shanks CA; Triggs EJ
    Clin Pharmacokinet; 1981; 6(1):25-60. PubMed ID: 7018787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure.
    Fahey MR; Rupp SM; Fisher DM; Miller RD; Sharma M; Canfell C; Castagnoli K; Hennis PJ
    Anesthesiology; 1984 Dec; 61(6):699-702. PubMed ID: 6239574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle relaxants in renal disease.
    Hunter JM
    Acta Anaesthesiol Scand Suppl; 1994; 102():2-5. PubMed ID: 7976159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium bromide.
    Szenohradszky J; Caldwell JE; Wright PM; Brown R; Lau M; Luks AM; Fisher DM
    Anesthesiology; 1999 Jan; 90(1):24-35. PubMed ID: 9915309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rocuronium bromide and organ function.
    Bevan DR
    Eur J Anaesthesiol Suppl; 1994; 9():87-91. PubMed ID: 7925215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of non-depolarizing curare-like drugs].
    Duvaldestin P
    Ann Anesthesiol Fr; 1981; 22(2):169-71. PubMed ID: 6115604
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of atracurium and its metabolites.
    Ward S; Weatherley BC
    Br J Anaesth; 1986; 58 Suppl 1():6S-10S. PubMed ID: 3754756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolism and excretion of main drugs used in anesthesia].
    Centi R; Lops V; Vandone A; Zaffiri O
    Minerva Anestesiol; 1971 Dec; 37(12):452-7. PubMed ID: 4259587
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients.
    Buck ML; Reed MD
    Clin Pharm; 1991 Jan; 10(1):32-48. PubMed ID: 1825627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status of our knowledge about various enzymatic processes of anesthesiologic interest. Biotransformation of various hypnotics, volatile anesthetics, and muscle relaxants].
    Castellani L
    Clin Ter; 1968 Feb; 44(3):253-67. PubMed ID: 4243639
    [No Abstract]   [Full Text] [Related]  

  • 19. A new short-acting non-depolarizing muscle relaxant (SZ1677) without cardiovascular side-effects.
    Vizi ES; Tuba Z; Mahó S; Foldes FF; Nagano O; Dóda M; Takagi S; Chaudhry IA; Saubermann AJ; Nagashima H
    Acta Anaesthesiol Scand; 2003 Mar; 47(3):291-300. PubMed ID: 12648195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Speed of action of various muscle relaxants at the neuromuscular junction binding vs. buffering hypothesis.
    Glavinovic MI; Law Min JC; Kapural L; Donati F; Bevan DR
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1181-6. PubMed ID: 8510002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.